Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis
Authors' conclusion
The Bayesian analysis adds substantial enhancement of the power of the study and supports a head-to-head trial of adalimumab and secukinumab for JIA-associated uveitis and chronic anterior uveitis.
Study context
- Population
- International experts in paediatric rheumatology, paediatric ophthalmology and/or paediatric uveitis, eliciting priors for children with juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis
- Participants
- 9 international experts
- Comparison
- Adalimumab vs secukinumab
- Outcome
- Prior expert opinion on response rate (consensus prior distribution)
Methodological detailsexpert consensus meeting, structured Bayesian prior elicitation meeting, international experts
- Expert consensus meeting
- Structured Bayesian prior elicitation meeting
- International experts
Recommendations
As reported in the abstract
Expected response rate (consensus prior)
| Group | Value | Equivalent sample size of prior |
|---|---|---|
| Adalimumab | mean 0.67 | 15.7 |
| Secukinumab | mean 0.55 | 13.1 |
Value
Adalimumabmean 0.67
Secukinumabmean 0.55
Equivalent sample size of prior
Adalimumab15.7
Secukinumab13.1
Original publication
Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis. Pediatr Rheumatol Online J. Published 19 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →